DGAP-News

​Lifestyle Delivery Systems gibt Abschluss der Broker- und nicht-Broker-Privatplatzierungsfinanzierungen bekannt - Seite 3

Im Namen vom Aufsichtsrat von Lifestyle Delivery Systems Inc.

Brad Eckenweiler

CEO & Direktor

Lifestyle Delivery Systems Inc.

FÜR WEITERE INFORMATIONEN KONTAKTIEREN SIE BITTE:
[e-mail]

Telefon: [phone]

Und


Skanderbeg Capital Advisors

[phone]
[e-mail]

Hinweis: Dies ist lediglich eine freie Übersetzung der ursprünglichen englischen Pressemitteilung. Nur die ursprüngliche englische Pressemitteilung ist verbindlich. Eine Haftung für die Richtigkeit der Übersetzung wird ausgeschlossen. Die originale Pressemitteilung kann auf der Webseite von Lifestyle Delivery Systems Inc. eingesehen werden: www.lifestyledeliverysystem.com

Original-Hinweis vom Unternehmen:

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release including, but not limited to, the timing and ultimate grant of a United States patent for the Sanderson technology, the timing and completion of the build out of the Adelanto Facility, and the complexity and evolving nature of the legal and regulatory landscape for medical and recreational marijuana in the State of California. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. Completion of the Adelanto Facility may be subject to uncertainties including the availability of trades people and obtaining the necessary occupancy permits, which may be outside of the Company's control. The Company does not have a history of earning revenues from the sale of products or the growing of cannabis products, and there is no assurance of future revenues. In addition, there is significant regulatory uncertainty with respect to the production and sale of medicinal and recreational marijuana in the United States of America. In particular, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. In addition, although the State of California has adopted laws permitting the commercial cultivation, extraction and manufacturing of medicinal marijuana, final regulations with respect to the implementation of these laws have yet to be adopted. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward- looking information.